News | May 31, 2021
Sun Pharmaceutical’s internals remain strong: ICICI Securities
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
The patients can check to see if the product purchased by them is genuine or not by scratching the surface and verifying the code through the app or the website
For the year ended March 31, 2021, consolidated revenue was at Rs. 10,943.9 crores as against Rs. 10,641 crores, recording an increase of 2.8% over the previous corresponding period
The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
Mucormycosis drug AmphoTLC will be imported from Taiwan by Stelis Biopharma Private Limited (Stelis), the biotech arm of Strides group, and will be launched and distributed in India immediately by Strides
MEK inhibitor compound (LNP3794) developed as part of its oncology pipeline had previously shown pre-clinical activity as a single agent as well as in combination
It is expected that the drug substance would be available from August 2021 which will be supplied back to Bharat Biotech for producing COVAXIN
Consequently, AstraZeneca India and Sun Pharma have now discontinued the Distribution Agreement signed in 2016 and have entered into a Transition Supply Agreement with effect from 28th May 2021
Cocktails of 2 mAbs based products are better equipped to deal with variants than single mAb based products which have a tendency of losing their efficacy with rapidly generating variants
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
Subscribe To Our Newsletter & Stay Updated
